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This study determines the distribution of pulmonary tuberculosis (PTB) among suspected patients and the resistance 
pattern of Mycobacterium tuberculosis to first line anti-tuberculosis drugs. 609 suspected PTB subjects (based on 
chest x-ray), attending tuberculosis clinic at Sacred Heart Hospital, Abeokuta, were involved in this study. Their 
blood samples were screened for HIV antibody using WHO strategy II, while sputum samples were screened for the 
presence of acid fast bacilli (AFB) using standard method. All AFB positive samples were cultured and 
susceptibility tests done using 1% proportion methods. Results showed that of the 609 subjects, 19.7% had PTB. 
The observed infection, though not statistically significant, was higher among males (21.6%) than in females. 
However, significant differences were observed for PTB infections amongst various age groups. Susceptibility test 
revealed that resistance to streptomycin was highest (33.0%) compared to other drugs, while detected multidrug-
resistant tuberculosis (MDR-TB) was 17.5%; being hiher among males (19.7%) and in subjects with PTB only
(19.3). In addition, mono-resistant and poly-resistance was found in 16.5% and 9.7% of the isolates respectively. 
These findings suggest that the control and prevention of PTB, especially MDR-TB, should include measures aimed 
at identifying the source of infection and proper tr a ment of infected individuals. 
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INTRODUCTION 
Tuberculosis is a global pandemic with 9.4 million ncident cases in 2009 and 1.7 million deaths (WHO, 2009). It is 
ranked seventh amongst causes of global morbidity and mortality (Muray and Lopez, 1997). In 2010, Niger a was 
ranked 4th among the 22 high tuberculosis burdened countries after India, China and South Africa (WHO, 2010a) 
and had  nearly 460,000 cases in 2009 with 193,200 being sputum positive (WHO, 2010a).  
 
Consequently, several anti-tuberculosis drugs have been developed. These drugs are usually classified as first-and 
second-line drugs (da Silva and Ainsa, 2007). The fiv  first-line drugs include Isoniazid (INH), Rifampicin (RIF), 
Pyrazinamide (PZA), Ethambutol (ETB) and Streptomycin (SM) while those classified as second-line drugs include 
the Aminoglycosides (Kanamycin and Amikacin), the Polypeptide (Capreomycin, Para-aminosalicylic acid, 
Cycloserine), the Thionamides (Ethionamide, and Prothionamide), and Fluoroquinolones such as Moxifloxacin, 
Levofloxacin and Gatifloxacin. 
 
The World Health Organisation (WHO) had recommended a standard regimen known as the Directly Observed 
Therapy, Short course (DOTS) (WHO, 1994), which consists of a 2 months initial phase of a daily dose of is niazid, 
rifampicin, pyrazinamide (ATS, 1986) and ethambutol (Grange 1998) and followed by a 4 month-continuation-
phase of isoniazid and rifampicin (ATS, 1986; Grange, 1998), given under direct observation (Schluger et al., 1996).  
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The emergence of multidrug-resistant tuberculosis (MDR-TB), [Strains of M. tuberculosis that are resistant to both 
isoniazid (INH) and rifampicin (RIF) with or without resistance to other drugs] (Domingo, 2007) is worris me 
because according to Dye et al., (2002), people with these strains, apart from transferring resistance strains to others, 
also fail treatment and thus, have a high risk of death. While resistance to either isoniazid or rifampicin may be 
treated with other first-line drugs, resistance to both isoniazid and rifampicin (MDR-TB) requires treatment with the 
second-line drugs such as Kanamycin, capreomycin, Para-aminosalicylic acid, cycloserine, ethionamide, 
levofloxacin and gatifloxacin (da Silva and Ainsa, 2007). These drugs have limited sterilizing effect and are not 
suitable for short course treatment (Sharma and Mohan, 2004). 
 
Early detection of drug resistance strains of M. tuberculosis constitutes one of the priorities in the control of 
tuberculosis. It allows early initiation of the appro riate treatment of patients harbouring such resistance strains, and 
also in surveillance of drug resistance (Martin and Portaels, 2007). Detection of drug resistance in tuberculosis 
control programme can be carried out using phenotypic method and genotypic method (Martin and Portaels, 2007). 
The phenotypic method is mainly based on detection of growth of M. tuberculosis in the presence of antibiotic 
incorporated into appropriate media. The detection of such resistant strains can be carried out using the so-called 
“conventional methods”. The genotypic methods detect he genetic determinant of resistance rather than the 
resistance phenotype. It involves two basic steps: nuclei acid amplification such as polymerase chain reaction 
(PCR), to amplify the sections of the M. tuberculosis genome that are altered in resistance strains; and a second step 
of assessing the amplified products for specific mutations correlating with drug resistance (Garcia de Viedma 2003; 
Palomino, 2005).   
 
Since infection with MDR-TB means that such species of mycobacteria has lost its response to the main b ctericidal 
drug –isoniazid, and the main sterilizing drug -rifampicin, the implication is that individuals infectd with these 
stains remain infectious for a longer period, both in the hospital and the community. Also they require at least 12 
months to possibly 24 months of treatment with lesseffective and more toxic second line drugs (Sharma and Mohan, 
2004).  
 
From the foregoing, data from countries like Nigeria are needed for proper and effective planning. This study 
therefore, intends to provide meaningful data on the distribution and resistance pattern of M. tuberculosis in Western 
Nigeria, as the availability of such data is limited in Nigeria. 
 
MATERIALS AND METHODS 
 
Study Area: This study was carried out in a Missionary Hospital in Abeokuta, a city in Western Nigeria. Abeokuta 
lies on latitude 7o15N and longitude 3o25E (Oyesiku and Kojeku, 1992). The city, which is about 81km South West 
of Ibadan and 106km North of Lagos, is located on an altitude of about 159m above sea level. It has a hot humid 
weather with annual rainfall of 963.3mm (Oyesiku and Kojeku, 1992).  Its population is estimated to be 451,607 
(National Bureau of Statistics, 2006). It has one Federal Medical Centre, few General Hospitals/Dental Clinics, 
several private hospitals/clinics and a Missionary Hospital (Sacred Heart Hospital), which apart from providing 
general health care delivery services, also serves as a referral centre for tuberculosis. 
 
Sampling Method: Purposive sampling method as described by Araoye (2004) was used for selecting patients 
clinically suspected of having pulmonary tuberculosis (PTB) based on X-ray radiography. Patients who were on 
admission or those receiving treatment were excluded.  
 
Sample size and duration: A total of six hundred and nine (609) subjects were finally selected for the study. The 
recruitment of samples lasted for two years (June, 2008 to May, 2010). 
 
Sample Collection/Ethical Considerations: With informed consent, three sputum specimens were coll cted from 
each subject.  These were ‘first spot’ specimen, an early morning specimen and a ‘second spot’ specimen (Horne, 
1996). Two millilitres of blood samples were also collected from each subject. 
 
Sample Analysis: The blood sample were screened for the presence of HIV antibody using the indirect solid phase 
enzyme immunoassay (EIA) method (immunocomb HIV-1 and HIV-2) as described by Orgenics. The screening was
done according to manufacturer’s instructions. 
 
All the sputum specimens were processed in a safety cabinet for the presence of acid fast bacilli (AFB) and using 
Ziehl-Neelsen method as the staining technique (IUATLD, 1986). All the AFB positive sputum were cultured into 
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Lowenstein Jensen medium after decontamination with N-acetyl-L-cystein sodium hydroxide (NALC-NaOH)  
solution as described by Kent and Kubica (1985). 
 
Preparation of drug solution and drug containing media: Isoniazid, rifampicin, streptomycin, ethambutol and 
pyrazinamide powders were obtained and were used to prepare bulk drug solutions with the following 
concentrations: Isoniazid (20µg/ml), rifampicin (4000µg/ml), ethambutol (200µg/ml), streptomycin (400µg/ml) and 
pyrazinamide (10000µg/ml) as described by Kent and Kubica (1985). The drug-containing Lowenstein Jensen 
medium was prepared by incorporating the various drugs into different Lowenstein Jensen medium before 
insipisation. 
 
The required drug dosage was as described by Fujiki (2001). For isoniazid, 4 ml from the isoniazid solution was 
added to 400 ml of raw Lowenstein Jensen medium in a sterile flask to give 0.2 µg/ml. For rifampicin, 4 ml from the 
rifampicin solution was added to 400 ml of raw Lowenstein Jensen medium in a sterile flask to give 2 µg/ml. For 
ethambutol, 4 ml of the ethambutol solution was added to 400 ml of raw Lowenstein Jensen medium in a sterile 
flask to give 2 µg/ml. For streptomycin, 4 ml of the streptomycin solution was added to 400 ml of raw Lo enstein 
Jensen medium in a sterile flask to give 4 µg/ml. For pyrazinamide, 4ml of the pyrazinamide solution was added to 
400ml of raw Lowenstein Jensen medium in a sterile flask to give 100 µg/ml. 
 
The drug containing raw media were mixed properly and kept in the fridge overnight for proper diffusion f the 
drugs.  Six millilitres [6ml] of the drug containing medium was later dispensed into sterile test tubes. The tubes were 
corked, labeled and inspissated at 90oC for 50 minutes.  Batches of drug free medium were also prepared for control. 
 
Preparation of 1mg/ml Tubercle Bacilli Suspension: For each positive culture growth, about 5 drops of terile 
distilled water were placed into a sterile screw capped test tube (homogenizer) containing about 5 – 6 sterile glass 
beads. Using a sterile wire loop, one loopful of M. tuberculosis complex growth was transferred into the 
homogenizer and was screw capped.  This was vortexed for 3 minutes and left for 10 minutes to prevent aerosol 
from being produced. Five millilitres (5ml) of steril  distilled water was added and the large particles were allowed 
to settle.  The supernatant suspension was transferred into another sterile test tube and was adjusted to that of 
MacFarland No 1 with sterile distilled water; this represents 1mg/ml bacillary suspension (Fujiki, 2001). 
 
For the susceptibility testing, 0.01 mg/ml bacillary suspension (100% proportion) is usually used (Fujiki, 2001).  
The 0.01 mg/ml bacillary suspension was prepared by making a 1 in 100 dilution of the 1mg/ml bacillary 
suspension. This was achieved by adding 0.1ml of the 1mg/ml bacillary suspension to 9.9 ml of sterile distilled 
water.  Another one in hundred (1/100) suspension was also made from the 0.01mg/ml bacillary suspension using 
sterile distilled water to produce 0.0001mg/ml (1% proportion) 
 
For each 0.01mg/ml bacillary suspension, one drug-fee (control) medium and a set of drug-containing media were 
inoculated with 0.1ml of the 0.01mg/ml suspension.  Another drug-free control medium was inoculated with 
0.0001mg/ml bacillary suspension (control of the 1% proportion). 
 
The inoculum was allowed to spread on the surface of the medium and kept at slanting position with loosened caps 
at 37oC in an incubator for one week and thereafter, the caps were tightened and incubation continued for 4 – 6 
weeks. Immediately enough growth was observed on the drug-free control medium, the drug-containing tubes were 
brought out and read. 
 
Interpretation of the susceptibility results: The growth on each of the drug containing medium was compared 
with the control tubes. No growth on the drug-containing medium or growth less than that of drug-free m dium at 
0.0001mg/ml dilution was recorded as sensitive (S) while growth on the drug-containing medium that was equal to 
or more than that on the drug-free medium at 0.0001mg/ml dilution was recorded as resistant (R). 
 
Data analysis: Data were analyzed using the SPSS package. The studnt t test or the chi-square test was performed 




Findings from this study revealed that of the 609 subjects examined, 315 were males while 294 were femal s. Sixty 
eight (68; 21.6%) of the males and fifty two (52; 17.7%) of the females had PTB. Though the PTB infection in 
males was higher than in females, the difference was not statistically significant (X2=1.462; P=0.227) (Table 1). 
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Fifty seven (57; 18.1%) of the males and forty six (46; 15.6%) of the females had PTB only but the difference is not 
statistically significant (X2=0.013; P=0.909) (Table 1). Eleven (11; 3.5%) of the males and six (6; 2.0%) of the 
females had PTB-HIV co-infection, but there was no significant difference in the infection rate (X2=1.511; 
P=0.219). Twelve (12; 3.9%) of the males and twenty (20; 6.8%) of the females had HIV infection only; the 
difference was however not statistically significant (X2=2.107; P=0.147) (Table 1). 
 
The distribution of the total PTB in relation to age roups of the subjects revealed that, of the 28 subjects that were 
within the age range of 15-19 years old, 11 (39.3%) had PTB. Similarly, 169 of the studied subjects were of age 
range 20-29 years old, 194 were 30-39 years old, 153 were 40-49 years old, 37 were 50-59 years old and 28 were 60 
years old and above. PTB infection rate among these age groups were 35 (20.7%), 34 (17.5%), 21 (13.7%) 8 
(21.6%) and 11 (39.3%) respectively. There was significa t difference in the total PTB infection rate in the various 
age groups (X2=17.80; P=0.003) (Table 1).   There was also significant difference in the total PTB infection rate 
among the various age groups of the female subjects (X2=17.57; P=0.004) (Table 1).   
 
 
TABLE 1:   DISTRIBUTION OF PTB AND PTB-HIV CO-INFEC TION AMONG THE STUDIED 






Number tested PTB  ONLY 
 
PTB-HIV  TOTAL PTB 
 
 
M F T M (%) F (%) T (%) M (%) F (%) T (%) M (%) F ( %) T (%) 
   15-19 11 17 28 3 (27.3) 7 (41.2) 10 (35.7) -  (0) 1 (5.2) 1 (3.6) 3(27.3) 8(47.1) 11(39.3) 

















































































































































         χ2 =  9.123             15.52             21.79       5.053         3.796        1.993           5.953             17.569                17.804 
                           P = 0.104               0.008             0.001            0.409          0.579       0.850            0.311             0.004                   0.003 
 
KEY : M = Male; F= Female; T = Total; HIV= Human Immunodeficiency Virus, PTB= Pulmonary Tuberculosis; 
PTB-HIV= Pulmonary Tuberculosis and HIV co-infection 
a  ⇒  χ2 = 0.013      P = 0.909, b ⇒  χ2 = 1.511     P = 0.219, c ⇒   χ2 = 1.462       P = 0.227 
 
 
Drug susceptibility pattern of the 103 isolates (61from the male and 42 from the female patients) revealed that the 
resistant strains were generally higher among males compared to females, but the difference was not statistically 
significant (P>0.05) (Table 2). Likewise, MDR-TB inmales 12 (19.7%) was also higher than that of femal s 
6(14.3%) but the difference was not statistically significant.(X2=0.500; P=0.480) (Table 2). Eleven of the 61 isolates 
in male and 6 of the 42 isolates in females were monoresistant but the difference was not statistically significant 
(X2=0.253; P=0.619) (Table 2). Polyresistant is also higher in the isolates from males 8 (13.1%) when compared to 
those of females, 2 (4.8%) but the difference was not statistically significant (X2=1.980; P=0.159) (Table 2). 
 
Susceptibility results of the M. tuberculosis complex isolates also showed that, of the total 103isolates (88 from 
PTB patients and 15 from PTB-HIV patients), multidrug resistant strains were recorded in one of the PTB-HIV 
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patient (6.7%) while 17 of the patients with PTB only had MDR-TB (19.3%) (Table 3). The sensitivity patterns 
recorded among the isolates from PTB patients and those from PTB-HIV patients showed no significant difference 
(P>0.05) (Table 3). 
 
 
TABLE 2a: DISTRIBUTION OF THE DRUG SUSCEPTIBILITY P ATTERNS OF M. TUBERCULOSIS 
COMPLEX BASED ON SEX OF THE SUBJECTS 
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     X2= 1.747 X2= 0.971 X2= 0.226 X2= 2.715 X2= 0.312 
     P=   0.186 P=   0.324 P= 0.635 P= 0.099 P= 0.576 
               
 
Key: M= Male; F=Female; RIF= Rifampicin; INH= Isoniazid; ETB=Ethambutol; STR= Streptomycin; 
PZA=Pyrazinamide; MOT=Mycobacteria other than tuberculosis; MTB-C = Mycobacterium tuberculosis complex; 
NCS=number of cultured sputum; N MTB-C I= Number of MTB-C isolated, NC= Number Contaminated 
 
 
TABLE 2b: DISTRIBUTION OF THE DRUG SUSCEPTIBILITY P ATTERNS OF M. TUBERCULOSIS 
COMPLEX BASED ON SEX OF THE SUBJECTS. 
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6  (11.5) 
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17    16.5) 
 
10   (9.7) 
            
     X2=  1.747 X2= 0.971 X2=0.500 X2=0.253 X2=1.980 
     P=   0.186 P= 0.324 P=0.480 P=0.615 P=0.159 
            
 
Key: RIF= Rifampicin; INH= Isoniazid; MDR-TB=Multidrug resistance tuberculosis; MOT=Mycobacteria other 
than tuberculosis; MTB-C = Mycobacterium tuberculosis complex; NCS=number of cultured sputum; N MTB-C I= 






Findings from this study revealed an overall PTB prevalence of 19.7% in Abeokuta Nigeria with prevalence among 
new cases being 16.0%. These findings are in agreement with reports from other parts of Nigeria. For example, in 
Umuahia, Abia state, a prevalence of 21.6% was report d (Nwachukwu and Peter, 2010).  Okodua et al. (2004) 
reported a prevalence of 21.7% in Edo State. In Maiduguri, Northern Nigeria, Ukwandu (1998) reported a 
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prevalence of 14.7% while Itah and Udofia (2005) reported a prevalence of 31.7% from South- Eastern Nigeria. In 
Lagos, a prevalence of 21.0% was reported by Idigbe and Onwujekwe (1983). The relatively lower prevalenc  
recorded in this study (19.7%) compared to that in South-Eastern Nigeria (31.7%) could be as a result of the 
differences in geographical location and effectiveness in the directly observed treatment short-course (DOTS) 
strategy currently being used for tuberculosis control programme. 
 
The highest prevalence reported for South- Eastern Nigeria (31.7%) could be due to higher population of 
inhabitants; as the main occupation in this region is trading which attracts more people from different locations. By 
this means, increasing the amount of infective droplets in the atmosphere and also increases the risk of being 
infected by TB. Higher inner city population and inhalation of infective droplets are risk factors fortuberculosis 
(Tomford, 2004). The higher PTB rate of 31.7% reported from South-Eastern Nigeria (Ita and Udofia, 2005) could 
also be due to the fact that the work was carried out during TB outbreak in the sub-region in March, 2001 (Ita and 
Udofia, 2005) and the work was carried out among patients on admission as well as out-patients.  The present study 
was however carried out among out patients only.  
 
The distribution of PTB by the gender of the subjects showed a higher prevalence among males 21.6% compared to 
females (17.7%). This trend of observation has alsobeen reported by various researchers. In South-East Asia and 
West Pacific regions, female to male PTB prevalence ratio of less than 0.5 was reported (Borgdorff et al., 2000). 
Itah and Udofia (2005) reported PTB prevalence of 35.5% among males and 26.9% among females in South-Eatern 
Nigeria. Idigbe and Onwujekwe (1983) had earlier repo ted PTB prevalence of 65% and 35% among males and 
females respectively in Lagos. The higher prevalence of PTB among males could be as a result of frequent contact 
with infective droplets from diseased patients in vehicles, work place, etc. when they go out for daily ctivities. 
Tuberculosis is acquired through in inhalation of infectious droplets (Rose, 1991; Stead, 1992). 
 
The relatively higher  MDR-TB among males (19.7%) compare to females (14.3%) as observed in this study is in 
line with reports from South Africa where a higher number of MDR-TB cases was recorded in males (4826 cases) 
than in females (4615 cases) (WHO, 2010b). Similarly, in countries of the former Solviet Union such as Lithuania, 
male TB patients were found to harbour MDR-TB strains more than female (WHO, 2010b). The higher MDR-TB 
among males in this study is at variance with report fr m China where a higher MDR-TB was recorded among 
females (19.0%) than in male (15.8%) (Shao et al., 2011). Reports from Australia, the Netherlands and U ited State 
of America showed that female TB patients harbor MDR-TB strains than male (WHO, 2010b). While males 
predominate among TB cases in most countries (WHO, 2010b), the variation in the effect of gender in harbouring 
MDR-TB is multifactorial. While the observation made from this study could be as a result of poor knowledge about 
TB as well as “male ego” that is common with males make them to seek alternative local herbs. 
 
The relatively lower prevalence of MDR-TB recorded among isolates from PTB-HIV subjects (6.7%) compared 
with those from patients with PTB only (19.3%) (P>0.05) showed that occurrence of resistance was not related to 
HIV infection. This observation has been reported by Eyob et al. (2004) who reported 5.3% of MDR-TB among 
PTB-HIV patients in Ethiopia. This work is however at variance to that of  Chakraborty et al., (2010) who reported 
17.7% and 6.6% MDR-TB in PTB-HIV patients and non HIV infected PTB patients respectively in India. The 
reason for this variation could be as a result of the high incidence of PTB in India which may have prdisposed them 
to high incidence of MDR-TB. India is rated first among the 22 world high burdened TB countries (WHO, 2010b). 
The surveillance of drug resistance in tuberculosis and most especially MDR-TB is a critical component of 
tuberculosis control. The benefits of this surveillance are numerous and these include increasing and strengthening 
of laboratory networks, improving on TB control prog amme and collection of adequate data. 
 
While the laboratory services are fundamental in the control of tuberculosis, they are often the weakest component 
in the system. The importance of the laboratory in the control of tuberculosis should be recognized anthe 
laboratory should be able to perform sputum smear mic oscopy, culture and drug susceptibility testing to enhance 
the diagnosis, control and management of tuberculosis. 
 
The prevalence of MDR-TB recorded in this study is (17.5%) is alarming. This calls for urgent interventio  and 
control measures. The control of tuberculosis especially the MDR-TB involves measures which are aimed at 
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